CLLS

NASDAQ open

Cellectis

0.91 USD
▼-0.07-7.50%
盘后 1.01 0.00%
2026-11-20
市值
$72.67M
市盈率
—
EPS
-1.22
股息率
—
52 周区间
0.88 – 5.45
成交量
25.80K
Beta
2.94
目标价
4.45
52W 低 0.8852W 高 5.45
价格走势

公司简介

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with...